Traws Pharma files IND for flu drug TXM; ratutrelvir beats Paxlovid on symptom resolution in interim study

Traws Pharma, Inc.

IND filed with FDA for tivoxavir marboxil (TXM) for influenza; final step for BARDA stockpile consideration.
Interim Phase 2 data: ratutrelvir showed faster symptom resolution vs Paxlovid (12 vs 14 days, p<0.014).
No viral rebound in ratutrelvir arm vs one in Paxlovid; fewer adverse events (7.6% mild dyspepsia vs 30% in comparator).
Ratutrelvir showed consistent safety and efficacy in Paxlovid-ineligible patients (13 patients).
Full study enrollment expected in January 2026; 95% of 90 patients enrolled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.